Program Overview
HER2 testing is an integral part of the standard of care for breast cancer; it not only provides an indication of prognosis, but also more importantly indicates likely response to HER2 targeted therapy. Therefore, as part of the standard of care for breast cancer, HER2 status should be assessed and used to direct therapy. However, several tests are available each with different strengths and weaknesses. While many of the shortcomings can be addressed through the application of good laboratory practice, controversy remains regarding the relative role of IHC and FISH, and the scoring and interpretation of the results. This program will review the most recent data, critique the ASCO/CAP guidelines and discuss the practical application of HER2 testing and provide recommendations which are relevant to everyday clinical practice.
Target Audience
The educational design of these activities addresses the needs of clinicians and nurses involved in the treatment of patients with breast cancer.
For information about the accreditation of this program
Please contact Global at Tel: (303) 395-1782 or inquire@globaleducationgroup.com.
Date of Activity: April 22, 2011
This activity is jointly sponsored by Global Education Group and Strategic Consultants International
This activity is supported by an educational grant from Genentech.
Educational Objectives
After completing this activity, the participant should be better able to:
- State the ASCO/CAP Guidelines for HER2 testing
- Review the criteria laboratories reporting HER2 results should adhere to
- Explain why samples may have intermediate HER2 status by IHC or FISH and the recommendations for further testing
- Describe appropriate treatment interventions for breast cancer according to HER2 status, including those with intermediate findings on pathology.
Faculty
 |
William J. Gradishar, MD, FACP - View
Biography Professor of Medicine Division of Hematology/Oncology Northwestern Medical Faculty Foundation Northwestern University Medical School Feinberg School of Medicine Chicago, IL |
 |
Michael F. Press, MD, PhD - View
Biography Professor of Pathology Norris Comprehensive Cancer Center (University of South California) Los Angeles, CA |
 |
Jeffrey S. Ross, MD - View
Biography Cyrus Strong Merrill Professor and Chair Department of Pathology and Laboratory Medicine Albany Medical College Albany, NY |
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter |
Reported Financial Relationship |
William J. Gradishar, MD, FACP |
Nothing to disclose |
Michael F. Press, MD, PhD |
Consultant Independent Contractor |
Jeffrey S. Ross, MD |
Consultant Independent Contractor |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to this content of this CME activity:
Name of Planner or Manager |
Reported Financial Relationship |
Jackie Dawson, MSN |
Nothing to disclose |
Amanda Glazar, PhD |
Nothing to disclose |
Ian Morgan, MSc |
Nothing to disclose |